Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort.
Alessandro SoriaMarco FavaDavide P BernasconiGiuseppe LapadulaElisa ColellaMaria G ValsecchiGuglielmo M MigliorinoRoberta D'AmbrosioSimona LandonioMonica SchiaviniAngiola SpinettiCanio CarrieroElisabetta DegasperiGiuliana CologniFederico GattiPaolo ViganòHamid HassonCaterina Uberti-FoppaLuisa PasuloChiara BaigueraRoberto RossottiMaria VinciMassimo PuotiAlessia GiorginiBarbara MenzaghiAndrea LombardiAngelo PanAlessio AghemoPaolo A GrossiRoberto BoldizzoniSilvia ColomboMauro ViganòMaria G RumiPaolo Del PoggioLuca Vittorio ValentiOmar GiglioAnna De BonaAntonella d'Arminio MonforteAlberto ColomboOmbretta SpinelliMarie G PigozziChiara MolteniPaolo BonfantiNatalia TerreniPaolo PeriniAndrea CaprettiDaniele BellaCecilia LianiSilvia PoloGianpiero AimoLayla PagnuccoSherrie BhooriRiccardo CentenaroMassimo GraffeoAntonio CiaccioElena DionigiSergio LazzaroniIsabella CarderiMariella Di MarcoGiuliano RizzardiniFranco NoventaPietro LamperticoStefano FagiuoliPublished in: Liver international : official journal of the International Association for the Study of the Liver (2020)
In a large real-life setting of HCV-GT3-infected patients with a high proportion of cirrhosis, the success rate was remarkable. The slight advantage of SOF/VEL on SOF + DAC was significant only without ribavirin. The current prescription shift towards novel regimens (ie SOF/VEL and GLE/PIB) in easier-to-treat patients allows ribavirin-free and shorter schedules without mining SVR12 in this <<difficult-to-treat>> genotype.